Received: 1 November 2022 | Revised: 7 December 2022 | Accepted: 12 December 2022

DOI: 10.14814/phy2.15553

ORIGINAL ARTICLE

Physiological Reports

HAND1 knockdown disrupts trophoblast global gene expression

Robert Fresch[1] | **Jennifer Courtney**[2] | **Heather Brockway**[3,4] | **Rebecca L. Wilson**[4,5] | **Helen Jones**[4,5]

[1]Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

[2]Center for Fetal and Placental Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

[3]Center for Scientific Review, National Institutes of Health, Bethesda, Maryland, USA

[4]Department of Physiology and Aging, University of Florida College of Medicine, Gainesville, Florida, USA

[5]Center for Research in Perinatal Outcomes, University of Florida College of Medicine, Gainesville, Florida, USA

Correspondence
Helen Jones, Center for Research in Perinatal Outcomes, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Email: jonesh@ufl.edu

Funding information
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Grant/Award Number: R01HD091527

Abstract

Congenital heart disease (CHD) affects nearly 1% of births annually, and CHD pregnancies carry increased risk of developing pathologies of abnormal placentation. We previously reported significant developmental impacts of disrupting *Hand1*, a gene associated with CHD, expression in placenta trophoblast and endothelial cells in multiple mouse models. In this study, we aimed to build upon this knowledge and characterize the mechanistic impacts of disrupting *HAND1* on human placenta trophoblast and vascular endothelial cell gene expression. *HAND1* gene expression was silenced in BeWo cells, a choriocarcinoma model of human cytotrophoblasts, (n = 3–9 passages) and isolated human placental microvascular endothelial cells (HPMVEC; n = 3 passages), with *HAND1* siRNA for 96 h. Cells were harvested, mRNA isolated and RNA sequencing performed using the Illumina NextSeq 550 platform. Normalization and differential gene expression analyses were conducted using general linear modeling in edgeR packages. Statistical significance was determined using a log2 fold change of >1.0 or <−1.0 and unadjusted p-value ≤0.05. Panther DB was used for overrepresentation analysis, and String DB for protein association network analysis. There was downregulation of 664 genes, and upregulation of 59 genes in BeWo cells with direct *HAND1* knockdown. Overrepresentation analysis identified disruption to pathways including cell differentiation, localization, and cell projection organization. In contrast, only seven genes were changed with direct *HAND1* knockdown in HPMVECs. Disruption to *HAND1* expression significantly alters gene expression profile in trophoblast but not endothelial cells. This data provides further evidence that future studies on genetic perturbations in CHDs should consider the extra-embryonic tissue in addition to the fetal heart.

KEYWORDS

congenital heart defects, Hand1, placenta, transcriptome

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Physiological Reports* published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

1 | INTRODUCTION

Congenital heart disease (CHD) affects nearly 1% of births annually, and often requires surgical intervention for repair and correction (van der Linde et al., 2011). Despite advances in care, CHD is still a leading cause of infant mortality from pregnancies complicated by birth defects accounting for approximately 4.2% of all neonatal deaths, and is associated with healthcare costs of approximately $6.1 billion dollars annually (Arth et al., 2017). About 25% of babies with CHD will have severe CHD (Oster et al., 2013), and the prevalence of CHD, particularly mild disease, is increasing. Pregnancies complicated with CHD also carry increased risk of developing pathologies of abnormal placentation including fetal growth restriction (FGR), preeclampsia, preterm birth, and stillbirth (Courtney et al., 2018). These adverse pregnancy outcomes greatly impact the after birth care required for the infant, specifically with regards to morbidity and mortality associated with surgery to correct the cardiac defect, as well as impacting childhood development and survival (Courtney et al., 2020).

Currently, we lack comprehensive understanding of the embryonic and fetal relationship between development of the placenta and the heart. The placenta is essential to fetal growth and development and placental dysfunction impacts perinatal outcomes (Burton & Fowden, 2015). This is because the placenta plays an essential role in regulating the transport of nutrients and oxygen from the mother to the fetus, and mediates maternal-fetal communication. In utero, initial heart and placenta development occurs in parallel during the first 3 weeks of gestation. We and others have shown common molecular pathways in placental and heart development (Courtney et al., 2021; Firulli et al., 2010). Using a systematic computational approach, we have shown numerous commonly expressed genes between first trimester human heart and placenta cells, which if disrupted may concurrently contribute to the developmental perturbations resulting in CHD (Wilson et al., 2022). Additionally, our lab has previously reported disrupted vascular development, and morphologic abnormalities and placental insufficiency in placentas from human pregnancies with CHD (Courtney et al., 2020; Jones et al., 2015). However, in-depth knowledge of the regulation of these common molecular pathways, particularly in relation to vasculogenesis and angiogenesis, is lacking. Additionally, studies using mice models to better understand heart development have also been shown to exhibit abnormal placental development, although the latter is very rarely investigated (Perez-Garcia et al., 2018).

HAND1 is a transcription factor related to the basic helix–loop–helix (bHLH) with essential roles in embryonic placenta and heart development (Firulli et al., 1998), and is expressed in first trimester human placental trophoblast (James et al., 2015; Telugu et al., 2013) and first trimester cardiac cells (Cui et al., 2019). Hand1-null mice are embryonic lethal by E8.5 due to defects in the extraembryonic tissues (Cserjesi et al., 1995; Firulli et al., 1998; Morikawa & Cserjesi, 2004; Riley et al., 1998). In mouse models where a knock-in stop codon is expressed on one allele of the *Hand1* gene ($Hand1^{A126fs/+}$) in specific cell types of the fetal heart because of different CRE drivers, embryonic lethality does not occur until gestational day 15.5 and fetuses exhibit outflow tract abnormalities, thin myocardium and ventricular septal defects (Firulli et al., 1998). More recently, we have shown that placentas of the $Nkx2.5^{Cre}/Hand1^{A126fs/+}$ mouse, in which the stop codon in the *Hand1* gene is knocked-in in chorion and labyrinth trophoblast progenitor cells, to expand labyrinth trophoblast precursor population, or develop appropriate syncytiotrophoblast and endothelium in the labyrinth (nutrient exchange area), by gestational day 10 resulting in fetal demise (Courtney et al., 2021). However, using the $Cdh5^{cre}/Hand1^{A126fs/+}$ mouse model, which results in a stop codon in the *Hand1* gene specifically in endothelial cells of the placenta and heart, the placentas are only affected in later-gestation with reduced placental vascular branching, but little effect on fetal heart development (Courtney et al., 2021). Signaling between trophoblast cells and villous endothelium is necessary for placental development and function, however there is a paucity of data looking at how signaling occurs at a molecular level during development. In this study, we aimed to build upon our discoveries in the mouse models and characterize the impact of disrupting *HAND1* expression on molecular signaling in human placenta trophoblast, and placental villous endothelial cells independently.

2 | MATERIALS AND METHODS

2.1 | BeWo and human placental microvascular endothelial cell culture

BeWo choriocarcinoma cell line (CCL-98, ATCC; fetal origin), which have physiological characteristics of the villous trophoblast (Gauster & Huppertz, 2010; Kudo et al., 2003), were maintained at 37°C, 5% CO_2 in Ham's F-12 medium (Sigma, St. Louis, MO) with 1% penicillin–streptomycin (Gibco, Waltham, MA), and 10% fetal bovine serum. Human Placenta Microvascular Endothelial Cells (HPMVECs) were isolated from term placentas under IRB approval (Good Samaritan Hospital and Cincinnati Children's Hospital Medical Center) as previously described (Troja et al., 2014). HPMVECs were cultured in T75 flasks pre-treated with attachment factor (Cell Applications Inc.) at 37°C, 5% CO_2 in EGM-2 media (Lonza, Allendale, NJ). Cells were subcultured every 3–4 days based on confluence estimates of

70%–90%. Experiments were conducted on cells at passages four to ten as standard in our cell culture protocols for BeWo and HPMVECs (Troja et al., 2014). Experimental replicates were performed in triplicate and biological replicates on at least three different passages.

2.2 | Direct *HAND1* knockdown in BeWo and HPMVECs

BeWo cells or HPMVECs were plated (2.5×10^5 cells/well) onto Millicell hanging cell culture inserts (Millipore, Bedford, MA) in 12 chamber culture trays with respective culture media in both the well insert chamber. For HPMVECs, the inserts were pre-coated with attachment factor. After 24 h, the well culture media was removed, cells washed with PBS, and replaced with treatment media: minimum essential media (MEM; Sigma, St. Louis, MO) containing 1% L-glutamine (Gibco, Waltham, MA) and 1% penicillin–streptomycin. To knockdown *HAND1* cells (n = 9 passages for BeWo cells and n = 3 passages for HPMVECs) were treated with 3 μl Lipofectamine +4 μl 10 μM *HAND1* siRNA for 96 h as laboratory standard (Jones et al., 2009). Treatment of cells with 3 μl Lipofectamine +3 μl 10 μM Allstars negative siRNA was used as a negative control. After 6 h, 10% FBS was added to ensure cell survival without starvation effects of MEM. At 96 h, cells were harvested for RNA isolation following treatment.

2.3 | Isolation of RNA and confirmation of *HAND1* knockdown via QPCR

Cells were lysed using RLT Buffer from Qiagen (Valencia, CA) following manufacturer's instructions. Total RNA was isolated using the RNeasy Mini Kit, QIAshredder, and on-column DNA digest (Qiagen) following the protocol provided by the manufacturer. For QPCR analysis, total RNA was quantified using a Nanodrop Spectrophotometer. One milligram of RNA was then converted to cDNA utilizing the Applied Biosystems High Capacity cDNA kit following manufacturer's protocol. QPCR was performed in duplicate reactions containing PowerUp SYBR Green (Applied Biosystems) as per manufacturer's instructions and with primers (Table S1) on the StepOne-Plus Real-Time PCR System (Applied Biosystems). Relative mRNA expression was calculated using the comparative CT method (Pfaffl, 2001) with the StepOne Software v2.3 (Applied Biosystems) normalizing genes to *ACTB*.

2.4 | Transcriptome generation and differential gene expression bioinformatic analyses

Total RNA was isolated from cells using same protocol as for QPCR. 50–100 μg of RNA from the various treated BeWo cells (n = 3), and HPMVECs (n = 3) was submitted to the University of Cincinnati Genomics, Epigenomics and Sequencing Core for RNA quality assessment and sequencing. RNA quality control (QC) was conducted on an Agilent 2100 Bioanalyzer for quality control. Only samples with a RNA integrity number (RIN) >8 were processed for sequencing. For each RNA sample, poly-A RNA libraries were generated using NEBNext Ultra Directional RNA Library Prep kits (New England Biolabs, Ipswich, MA), and the TruSeq SR Cluster kits (v3, Illumina). Transcriptomes were generated on the Illumina NextSeq 550 platform with ~25 million reads per sample with a single end read length between





FIGURE 1 *HAND1* mRNA expression in BeWo cells and human placental microvascular endothelial cells (HPMVECs) following siRNA treatment. (a) In BeWo cells, *HAND1* mRNA expression was reduced by 61% compared to Allstar negative control treatment after 96 h. (b) In HPMVECs, *HAND1* mRNA expression was reduced by 69% compared to Allstar negative control treatment after 96 h. data are median ± interquartile range. Statistical significance was determined using Mann–Whitney test. BeWo n = 9. HPMVEC n = 3.

TABLE 1 Biological processes impacted by direct knockdown of the *HAND1* gene in BeWo cells

	Fold enrichment	Adjusted *p*-value[a] Bonferroni
GO biological process: Developmental processes (GO:0032502)		
Reactome pathways		
MET activates PTK2 signaling (R-HSA-8874081)	17.2	4.11 E-02
Organelle biogenesis and maintenance (R-HSA-1852241)	4.6	1.74 E-02
Signal transduction (R-HSA-162582)	1.89	1.73 E-02
GO biological process: Cell projection and organization (GO:0030030)		
Panther pathways		
Organelle biogenesis and maintenance (R-HSA-1852241)	10.2	1.47 E-06
Signaling by Rho GTPases (R-HSA-194315)	6.04	5.16 E-03
GO biological process: Regulation of localization (GO:0032879)		
Panther pathways		
Integrin signaling pathway (P00034)	5.29	2.79 E-02
Reactome Pathways		
MET activates PTK2 signaling (R-HSA-8874081)	21.06	1.56 E-02
Cardiac conduction (R-HSA-5576891)	9.09	5.99 E-04
Muscle contraction (R-HSA-397014)	6.08	1.87 E-02
GO biological process: Establishment of localization (GO:0051234)		
Reactome pathways		
ABC-family proteins mediated transport (R-HSA-382556)	7.16	1.81 E-02
Membrane Trafficking (R-HSA-199991)	3.63	1.75 E-05
GO biological process: Regulation of multicellular organismal process (GO:0051239)		
Panther pathways		
TGF-beta signaling pathway (P00052)	7.98	2.24 E-02
Gonadotropin-releasing hormone receptor pathway (P06664)	7.86	9.78 E-07
EGF receptor signaling pathway (P00018)	6.71	1.76 E-02
Reactome pathways		
Toll-like receptor cascades (R-HSA-168898)	8.57	9.80 E-04
Cardiac conduction (R-HSA-5576891)	8.44	4.22 E-03
Toll like receptor 4 (TLR4) Cascade (R-HSA-166016)	8.27	1.82 E-02

[a]Statistical significance of over-representation was determined using Fisher's Exact Test with Bonferroni corrections for multiple corrections.

85–101 bp. Initial quality control for post-sequencing reads, read alignment, and read count generation were all performed in the public Galaxy Bioinformatic server (Boekel et al., 2015) utilizing the following tools: FASTQC (Andrews et al., 2010), trimmomatic (Bolger et al., 2014), Bowtie2 (Langmead & Salzberg, 2012), and featurecounts (Liao et al., 2014). All samples were then aligned utilizing the hg38 genome build via Bowtie2, which allowed for more precise alignments of the numerous homologous genes expressed in these specific cell lines. For each different experiment, gene count matrices were generated using featurecounts and utilized for

differential gene expression analyses. Differential gene expression analyses were conducted using the Empirical analysis of digital gene expression in R (EdgeR) package (Robinson et al., 2010). General linear modeling using the following pairwise comparisons were performed between, untreated controls, Allstars negative control treated, direct *HAND1* knockdown treated BeWo and HPMVEC cells that were treated directly. Multiple corrections testing yielded no statistical differences in the pairwise comparisons. Therefore, we used the raw p-values to determine genes to be used in overrepresentation analysis to identify pathways and processes rather than individual genes. RNA sequencing data have been deposited to NCBI GEO under the accession GSE209620.

2.5 | Overrepresentation analysis

2.5.1 | Panther DB evaluation

Lists of significantly differentially expressed genes identified between Allstar negative control and *HAND1* siRNA treated BeWos and HPMVECs were analyzed by PantherDB (Panther15.0) to determine over-representation and identify pathways and processes involved in trophoblast- endothelial cell signaling. Gene names were submitted with statistical testing conducted using Fisher's Exact test with multiple corrections testing via Bonferroni correction. We conducted analyses using Panther pathways, Reactome pathways, and GO Biological Processes against the entire genome for Homo sapiens.

2.5.2 | In silico StringDB assessment of interaction networks

StringDB (version 11.0) was utilized to assess potential protein interactions affected by knockdown of *HAND1* in BeWo cells. Seven significantly differentially expressed genes with large fold-changes were individually entered into StringDB and then functional interactions classified into biological pathways. Parameters were set at Homo Sapiens, Experimental and Database sources, Full Network Search.

2.6 | Statistical analysis

qPCR data were analyzed in Prism v8 (GraphPad) using either Kruskal–Wallis test with Dunn's multiple comparison test or Mann–Whitney test. Data for qPCR is presented as the median ± interquartile range.

3 | RESULTS

3.1 | *HAND1* siRNA treatment knocked-down *HAND1* expression in BeWo cells and HPMVECs

Compared to Allstar negative control treated cells, treatment with *HAND1* siRNA for 96 h reduced *HAND1* expression 61% in BeWo and 69% HPMVECs (Figure 1a,b, respectively).

3.2 | Direct *HAND1* siRNA treatment in BeWo cells resulted in changes to global gene expression

Compared to Allstar negative control, *HAND1* knockdown in BeWo cells resulted in downregulation of 664 genes, and upregulation of 59 genes (Data S1). PantherDB was utilized to perform overrepresentation analysis against Panther pathways, Reactome pathways, and Gene Ontology (GO) Biological processes on the differentially expressed genes. No overrepresentation was seen compared to Panther and Reactome pathways, however many results were returned for GO Biological processes (Table S2). Groups of genes identified as significantly overrepresented in GO Biological processes were then re-entered into PantherDB and indicated potential disruption to pathways including cell development, cellular projection, regulation and establishment of localization, and regulation of multicellular function (Table 1). There were several biological pathways over-represented, including GnRH releasing hormone pathways, cardiac conduction and signaling, TGF-beta signaling, and signaling of RHO

TABLE 2 Differentially expressed genes with large fold-change differences in BeWo cells in which HAND1 was knocked down

Gene (Ensembl gene ID)	Log2 FC	Raw *p*-value[a]
Upregulated		
CALML5 (ENSG00000178372)	4.6384	0.0012
NUBP1 (ENSG00000103274)	4.2640	0.0124
TFAP2E (ENSG00000116819)	3.5473	0.0041
WNT8A (ENSG00000061492)	2.9174	0.0065
Downregulated		
FAM49B (ENSG00000153310)	−5.8251	0.0001
CTTNBP2 (ENSG00000077063)	−5.6647	0.0007
NFS1 (ENSG00000244005)	−5.4039	0.0001

Abbreviation: FC, fold-change.

[a]Statistical testing applied within edgeR general linear models.

GTPases. In addition, there was significant enrichment in MET activating PTK2 signaling, and pathways related to signal transduction.

StringDB network analysis of seven genes with large (>2 or < −5) fold change differences in expression following *HAND1* knockdown in BeWo cells were found to be involved in biological pathways with known importance in growth and development (Table 2). Upregulated genes were *CALML5*, *NUBP1*, *TFAP2E*, and *WNT8A*. Downregulated genes; *FAM49B*, *CTTNBP2*, and *NFS1*. Reactome pathways examined identified common relationships between the genes including Beta-catenin phosphorylation, TGF-beta signaling, and PI3K-Akt signaling. Other notable biological pathways included cardiac conduction and calcium channel signaling, GnRH and Estrogen dependent gene expression, eNOS activation and regulation, and iron–sulfur and sulfur metabolism pathways and RHO GTPases (Figure 2).

3.3 | Direct treatment of HPMVECs with *HAND1* siRNA minimally disrupted global gene expression

Direct *HAND1* knockdown in HPMVECs resulted in minimal disruption to global gene expression with differential

FIGURE 2 Network analyses of genes disrupted by HAND1 knockdown in BeWo. Expression of *CALML5* (a), *NUBP1* (b), *TFAP2E* (c), and *WNT8A* (d) was significantly upregulated in BeWo cells treated with *HAND1* siRNA when compared to Allstar negative control. Expression of *FAM49B* (e), *CTTNBP2* (f), and *NFS1* (g) was significantly downregulated in BeWo cells treated with *HAND1* siRNA when compared to Allstar negative control. Gray lines represent the network edges with thickness representing the confidence of the data support (thicker lines = higher confidence data). Color coded legends show genes in Reactome pathways that may be impacted by *HAND1* knockdown.

expression in just seven genes (Table 3). QPCR validation on RNA samples independent of those used for RNA sequencing, confirmed two genes of interest, *GADD45g* and *NPPB* as reduced and increased, respectively in *HAND1* siRNA treated HPMVECs when compared to Allstar negative control (Figure 3).

4 | DISCUSSION

CHDs are often associated with pregnancy complications such as fetal growth restriction and preeclampsia, these conditions negatively impact clinical outcomes, increase the risk of neonatal morbidity and mortality, and are likely a consequence of abnormal placental development and function (Cnota et al., 2013; Laas et al., 2012; Puri et al., 2018; Ruiz et al., 2016; Tararbit et al., 2018). We have previously shown in mice, that targeted loss of *Hand1* in chorionic and labyrinthine progenitor trophoblasts led to abnormal formation of the placental labyrinth, and ultimately embryonic lethality (Courtney et al., 2021). Histological analysis of the placenta indicated that loss of *Hand1* in labyrinthine progenitor trophoblasts early in pregnancy significantly impacted the ability for the placenta to form syncytial layers, and impacted development of the labyrinthine vasculature. In this study we aimed to gain further mechanistic, translational understanding of the effects of *HAND1* knockdown in models of human placenta trophoblast and villous endothelial cells. We demonstrated significant alterations to placental trophoblast gene expression following *HAND1* knockdown, and identified potential pathways which may be significantly impacted by loss of *HAND1* regulation. This study is the first to identify possible molecular signaling pathways that are impacted by disruption to *HAND1* in the human placenta.

TABLE 3 Significantly differentially expressed genes in human placenta microvascular endothelial cells in which HAND1 was knocked down

Gene (Ensembl gene ID)	Log2 FC	Raw *p*-value[a]
Upregulated		
NPPB (ENSG00000120937)	1.5991	0.0001
DMKN (ENSG00000161249)	1.5035	0.0019
CHRDL2 (ENSG00000054938)	1.4178	0.0044
Downregulated		
ARC (ENSG00000198576)	−1.8451	0.0000
ELAVL3 (ENSG00000196361)	−1.8349	0.0009
HKDC1 (ENSG00000156510)	−1.6111	0.0049
GADD45G (ENSG00000130222)	−1.4619	0.0071

Abbreviation: FC, fold-change.

[a] Statistical testing applied within edgeR general linear models.

Overall, there were 664 genes differentially expressed in BeWo cells due to *HAND1* knockdown. Overrepresentation analyses reveals several key GO Biological Processes including: cell development, establishment of localization, and regulation of multicellular function, as well as biological pathways including Pl3K-Akt signaling, signaling Rho GTPases, and TLR cascades. Trophoblast differentiation during the first trimester of pregnancy involves trophoblast proliferation, invasion, and extracellular matrix (ECM) remodeling. PI3K/Akt signaling reduction or inhibition plays an important role in trophoblast proliferation, migration, and survival. Disruption to PI3K/Akt signaling in early embryonic development is associated with growth restriction, preterm birth, and embryonic lethality (Yu & Cui, 2016), highlighting the importance of this signaling pathway to placental development and function. Additionally, inhibition of PI3K increases soluble fms-like tyrosine kinase 1 (sFlt1), a common biomarker of pre-eclampsia (Park et al., 2010). PI3K/Akt signaling has been closely linked to signaling Rho-GTPases which are known to play a role in trophoblast migration (Duquette & Lamarche-Vane, 2014; Gupta et al., 2016).

TLR cascades form the major family of pattern recognition receptors that are involved in innate immunity. The maternal-fetal interface immunologically is unique in that it must promote tolerance of the fetus while maintaining protection to the mother. Trophoblasts play an important role in modulating the maternal immune response throughout pregnancy, including through TLR signaling (Koga & Mor, 2010). Additionally, TLR signaling has been shown to potentially modulate angiogenesis as culture of trophoblasts with TLR2 ligand HKML have been shown to promote the expression of pro-angiogenic Placenta Growth Factor (Kato et al., 2017). Overall, poor migration of trophoblasts, and communication with resident immune cells, can impact invasion and establishment of a fully functional maternal-fetal interface.

Expression of *CALML5* and *NUBP1* was upregulated in BeWo cells following *HAND1* knockdown. Both genes are involved with Calcium channel signaling, GnRH signaling, cAMP signaling, eNOS activation, and Pl3K-Akt signaling pathways. These are important biological pathways that impact trophoblast invasion, differentiation, development, resource control, and growth of the placenta and fetus (Liu et al., 2009; Moreau et al., 2002), and increased gene expression of *CALML5* and *NUBP1* may be a compensatory response to disruption of other signaling pathways. On the other hand, expression of *CTTNBP2* and *NSF1* was downregulated in BeWo cells in which *HAND1* was knocked down. *CTTNBP2* has been shown to have a direct relationship with the WNT





FIGURE 3 qPCR validation of two genes shown to be differentially expressed using RNA sequencing. (a) mRNA expression of *GADD45G* was shown to be reduced in *HAND1* siRNA treated human placenta microvascular endothelial cells (HPMVECs) when compared to Allstar negative control treated cells. (b) Expression of *NPPB* was increased in in *HAND1* siRNA treated HPMVECs when compared to Allstar negative control treated cells. Data are median ± interquartile range. Statistical significance was determined using Mann–Whitney test. $n = 3$ passages.

signaling pathway (Kelly et al., 2017), and downregulation in WNT signaling in the placenta has been associated with pathological pregnancies (Zmijanac Partl et al., 2018). Similarly, *NFS1* is a gene that has an essential role in iron–sulfur cluster processing making it important for electron transport, enzyme catalysis, and regulation of gene expression as well is iron homeostasis (Brzoska et al., 2006). Fetal growth is very dependent on energy metabolism in the placenta as it drives exchange of nutrients and plays a crucial role in DNA synthesis. Overall, our data indicates potential disruption to these pathways with *HAND1* knockdown and provides further understanding of how a genetic perturbation in this gene may lead to growth issues, developmental defects, and lethality/miscarriage in the context of human pregnancies with CHDs.

We sought to analyze the effect of *HAND1* knockdown in cells within the villous environment. Interestingly, direct *HAND1* knockdown in villous endothelial cells resulted in minimal impact to gene expression. This result however, is in agreement with our mouse model studies suggest that disrupting *Hand1* expression directly in labyrinthine endothelial cells impacted vascular remodeling only in late pregnancy and non-branching angiogenesis mechanisms (Courtney et al., 2021) not as individual endothelial cells or vasculogenesis. HPMVECs are cultured as a single monolayer. Therefore, it would be interesting for future studies, beyond the scope of the current study, to assess angiogenesis and remodeling mechanisms in a 3D vascularized model when HAND1 is knocked down or cultured in "conditioned" media from BeWo cells treated with *HAND1* siRNA. Cell–cell communication/signaling within the placenta villi in the human is believed to be important in establishment of the villous structure and exchange region but given our current data, the involvement of other cell types such as stromal fibroblasts in the communication process requires future investigation.

We and others have consistently shown that *HAND1* is important to both fetal heart and placenta development (Courtney et al., 2021; Firulli et al., 2010), with the present study providing further mechanistic understanding of how *HAND1* may influence the development of the placenta in the human. Given our data shows greater disruption to global gene expression in placenta trophoblasts then endothelial cells with *HAND1* knockdown, this further highlights the importance of future research to consider analyzing the extra-embryonic tissue, as well as the heart, in the context of CHD.

AUTHOR CONTRIBUTIONS

RF conceived the study, performed experiments, analyzed the data, and wrote the manuscript. JC performed experiments, analyzed data, and edited manuscript. HB performed bioinformatic analysis and interpretation, and edited manuscript. RLW analyzed data and wrote manuscript. HNJ obtained funding, conceived study, and edited the manuscript. All authors approved final version of manuscript.

FUNDING INFORMATION

This study was funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development award R01HD091527 (HNJ).

CONFLICT OF INTEREST

The authors report no conflict of interest. This article was prepared while Dr. Brockway was employed University of Florida. The opinions expressed in this article are the author's own and do not reflect the view of the National Institutes of Health, the Department

of Health and Human Services, or the United States government.

DATA AVAILABILITY STATEMENT

RNA sequencing data have been made publicly available in NCBI GEO, accession number: GSE209620. All other data can be provided upon request.

ORCID

Rebecca L. Wilson https://orcid.org/0000-0002-3867-7784
Helen Jones https://orcid.org/0000-0001-7356-8420

REFERENCES

Andrews, S.; Krueger, F.; Segonds-Pichon, A.; Biggins, L.; Krueger, C.; Wingett, S. (2010). *FastQC: A quality control tool for high throughput sequence data*. Babraham Bioinformatics.

Arth, A. C., Tinker, S. C., Simeone, R. M., Ailes, E. C., Cragan, J. D., & Grosse, S. D. (2017). Inpatient hospitalization costs associated with birth defects among persons of all ages - United States, 2013. *MMWR. Morbidity and Mortality Weekly Report*, *66*, 41–46. https://doi.org/10.15585/mmwr.mm6602a1

Boekel, J., Chilton, J. M., Cooke, I. R., Horvatovich, P. L., Jagtap, P. D., Kall, L., Lehtio, J., Lukasse, P., Moerland, P. D., & Griffin, T. J. (2015). Multi-omic data analysis using galaxy. *Nature Biotechnology*, *33*, 137–139. https://doi.org/10.1038/nbt.3134

Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics*, *30*, 2114–2120. https://doi.org/10.1093/bioinformatics/btu170

Brzoska, K., Meczynska, S., & Kruszewski, M. (2006). Iron-sulfur cluster proteins: Electron transfer and beyond. *Acta Biochimica Polonica*, *53*, 685–691.

Burton, G. J., & Fowden, A. L. (2015). The placenta: A multifaceted, transient organ. *Philosophical Transactions of the Royal Society of London Series B, Biological Sciences*, *370*, 20140066. https://doi.org/10.1098/rstb.2014.0066

Cnota, J. F., Hangge, P. T., Wang, Y., Woo, J. G., Hinton, A. C., Divanovic, A. A., Michelfelder, E. C., & Hinton, R. B. (2013). Somatic growth trajectory in the fetus with hypoplastic left heart syndrome. *Pediatric Research*, *74*, 284–289. https://doi.org/10.1038/pr.2013.100

Courtney, J., Troja, W., Owens, K. J., Brockway, H. M., Hinton, A. C., Hinton, R. B., Cnota, J. F., & Jones, H. N. (2020). Abnormalities of placental development and function are associated with the different fetal growth patterns of hypoplastic left heart syndrome and transposition of the great arteries. *Placenta*, *101*, 57–65. https://doi.org/10.1016/j.placenta.2020.09.007

Courtney, J. A., Cnota, J. F., & Jones, H. N. (2018). The role of abnormal placentation in congenital heart disease; cause, correlate, or consequence? *Frontiers in Physiology*, *9*, 1045. https://doi.org/10.3389/fphys.2018.01045

Courtney, J. A., Wilson, R. L., Cnota, J., & Jones, H. N. (2021). Conditional mutation of Hand1 in the mouse placenta disrupts placental vascular development resulting in fetal loss in both early and late pregnancy. *International Journal of Molecular Sciences*, *22*, 9532. https://doi.org/10.3390/ijms22179532

Cserjesi, P., Brown, D., Lyons, G. E., & Olson, E. N. (1995). Expression of the novel basic helix-loop-helix gene eHAND in neural crest derivatives and extraembryonic membranes during mouse development. *Developmental Biology*, *170*, 664–678. https://doi.org/10.1006/dbio.1995.1245

Cui, Y., Zheng, Y., Liu, X., Yan, L., Fan, X., Yong, J., Hu, Y., Dong, J., Li, Q., Wu, X., Gao, S., Li, J., Wen, L., Qiao, J., & Tang, F. (2019). Single-cell transcriptome analysis maps the developmental track of the human heart. *Cell Reports*, *26*, 1934–1950e1935. https://doi.org/10.1016/j.celrep.2019.01.079

Duquette, P. M., & Lamarche-Vane, N. (2014). Rho GTPases in embryonic development. *Small GTPases*, *5*, 8. https://doi.org/10.4161/sgtp.29716

Firulli, A. B., McFadden, D. G., Lin, Q., Srivastava, D., & Olson, E. N. (1998). Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1. *Nature Genetics*, *18*, 266–270. https://doi.org/10.1038/ng0398-266

Firulli, B. A., McConville, D. P., Byers, J. S., 3rd, Vincentz, J. W., Barnes, R. M., & Firulli, A. B. (2010). Analysis of a Hand1 hypomorphic allele reveals a critical threshold for embryonic viability. *Developmental Dynamics*, *239*, 2748–2760. https://doi.org/10.1002/dvdy.22402

Gauster, M., & Huppertz, B. (2010). The paradox of caspase 8 in human villous trophoblast fusion. *Placenta*, *31*, 82–88. https://doi.org/10.1016/j.placenta.2009.12.007

Gupta, S. K., Malhotra, S. S., Malik, A., Verma, S., & Chaudhary, P. (2016). Cell signaling pathways involved during invasion and Syncytialization of trophoblast cells. *American Journal of Reproductive Immunology*, *75*, 361–371. https://doi.org/10.1111/aji.12436

James, J. L., Hurley, D. G., Gamage, T. K., Zhang, T., Vather, R., Pantham, P., Murthi, P., & Chamley, L. W. (2015). Isolation and characterisation of a novel trophoblast side-population from first trimester placentae. *Reproduction*, *150*, 449–462. https://doi.org/10.1530/REP-14-0646

Jones, H. N., Jansson, T., & Powell, T. (2009). IL-6 stimulates system a amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2. *American Journal of Physiology-Cell Physiology*, *297*, C1228–C1235.

Jones, H. N., Olbrych, S. K., Smith, K. L., Cnota, J. F., Habli, M., Ramos-Gonzales, O., Owens, K. J., Hinton, A. C., Polzin, W. J., Muglia, L. J., & Hinton, R. B. (2015). Hypoplastic left heart syndrome is associated with structural and vascular placental abnormalities and leptin dysregulation. *Placenta*, *36*, 1078–1086. https://doi.org/10.1016/j.placenta.2015.08.003

Kato, E., Yamamoto, T., & Chishima, F. (2017). Effects of cytokines and TLR ligands on the production of PlGF and sVEGFR1 in primary trophoblasts. *Gynecologic and Obstetric Investigation*, *82*, 39–46.

Kelly, A. C., Bidwell, C. A., McCarthy, F. M., Taska, D. J., Anderson, M. J., Camacho, L. E., & Limesand, S. W. (2017). RNA sequencing exposes adaptive and immune responses to intrauterine growth restriction in fetal sheep islets. *Endocrinology*, *158*, 743–755. https://doi.org/10.1210/en.2016-1901

Koga, K., & Mor, G. (2010). Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders.

American Journal of Reproductive Immunology, *63*, 587–600. https://doi.org/10.1111/j.1600-0897.2010.00848.x

Kudo, Y., Boyd, C. A., Kimura, H., Cook, P. R., Redman, C. W., & Sargent, I. L. (2003). Quantifying the syncytialisation of human placental trophoblast BeWo cells grown in vitro. *Biochimica et Biophysica Acta*, *1640*, 25–31. https://doi.org/10.1016/s0167-4889(03)00004-1

Laas, E., Lelong, N., Thieulin, A. C., Houyel, L., Bonnet, D., Ancel, P. Y., Kayem, G., Goffinet, F., Khoshnood, B., & Group, E.S. (2012). Preterm birth and congenital heart defects: A population-based study. *Pediatrics*, *130*, e829–e837. https://doi.org/10.1542/peds.2011-3279

Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with bowtie 2. *Nature Methods*, *9*, 357–359. https://doi.org/10.1038/nmeth.1923

Liao, Y., Smyth, G. K., & Shi, W. (2014). featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*, *30*, 923–930. https://doi.org/10.1093/bioinformatics/btt656

Liu, J., Maccalman, C. D., Wang, Y. L., & Leung, P. C. (2009). Promotion of human trophoblasts invasion by gonadotropin-releasing hormone (GnRH) I and GnRH II via distinct signaling pathways. *Molecular Endocrinology*, *23*, 1014–1021. https://doi.org/10.1210/me.2008-0451

Moreau, R., Hamel, A., Daoud, G., Simoneau, L., & Lafond, J. (2002). Expression of calcium channels along the differentiation of cultured trophoblast cells from human term placenta. *Biology of Reproduction*, *67*, 1473–1479. https://doi.org/10.1095/biolreprod.102.005397

Morikawa, Y., & Cserjesi, P. (2004). Extra-embryonic vasculature development is regulated by the transcription factor HAND1. *Development*, *131*, 2195–2204. https://doi.org/10.1242/dev.01091

Oster, M. E., Lee, K. A., Honein, M. A., Riehle-Colarusso, T., Shin, M., & Correa, A. (2013). Temporal trends in survival among infants with critical congenital heart defects. *Pediatrics*, *131*, e1502–e1508. https://doi.org/10.1542/peds.2012-3435

Park, J. K., Jeong, J. W., Kang, M. Y., Baek, J. C., Shin, J. K., Lee, S. A., Choi, W. S., Lee, J. H., & Paik, W. Y. (2010). Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro. *Placenta*, *31*, 621–629. https://doi.org/10.1016/j.placenta.2010.04.009

Perez-Garcia, V., Fineberg, E., Wilson, R., Murray, A., Mazzeo, C. I., Tudor, C., Sienerth, A., White, J. K., Tuck, E., Ryder, E. J., Gleeson, D., Siragher, E., Wardle-Jones, H., Staudt, N., Wali, N., Collins, J., Geyer, S., Busch-Nentwich, E. M., Galli, A., … Hemberger, M. (2018). Placentation defects are highly prevalent in embryonic lethal mouse mutants. *Nature*, *555*, 463–468. https://doi.org/10.1038/nature26002

Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Research*, *29*, e45–e445.

Puri, K., Warshak, C. R., Habli, M. A., Yuan, A., Sahay, R. D., King, E. C., Divanovic, A., & Cnota, J. F. (2018). Fetal somatic growth trajectory differs by type of congenital heart disease. *Pediatric Research*, *83*, 669–676. https://doi.org/10.1038/pr.2017.275

Riley, P., Anson-Cartwright, L., & Cross, J. C. (1998). The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. *Nature Genetics*, *18*, 271–275. https://doi.org/10.1038/ng0398-271

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, *26*, 139–140. https://doi.org/10.1093/bioinformatics/btp616

Ruiz, A., Ferrer, Q., Sanchez, O., Ribera, I., Arevalo, S., Alomar, O., Mendoza, M., Cabero, L., Carrerras, E., & Llurba, E. (2016). Placenta-related complications in women carrying a foetus with congenital heart disease. *The Journal of Maternal-Fetal & Neonatal Medicine*, *29*, 3271–3275. https://doi.org/10.3109/14767058.2015.1121480

Tararbit, K., Lelong, N., Goffinet, F., Khoshnood, B., & Group, E.S. (2018). Assessing the risk of preterm birth for newborns with congenital heart defects conceived following infertility treatments: A population-based study. *Open Heart*, *5*, e000836. https://doi.org/10.1136/openhrt-2018-000836

Telugu, B. P., Adachi, K., Schlitt, J. M., Ezashi, T., Schust, D. J., Roberts, R. M., & Schulz, L. C. (2013). Comparison of extravillous trophoblast cells derived from human embryonic stem cells and from first trimester human placentas. *Placenta*, *34*, 536–543. https://doi.org/10.1016/j.placenta.2013.03.016

Troja, W., Kil, K., Klanke, C., & Jones, H. N. (2014). Interaction between human placental microvascular endothelial cells and a model of human trophoblasts: Effects on growth cycle and angiogenic profile. *Physiological Reports*, *2*, e00244. https://doi.org/10.1002/phy2.244

van der Linde, D., Konings, E. E., Slager, M. A., Witsenburg, M., Helbing, W. A., Takkenberg, J. J., & Roos-Hesselink, J. W. (2011). Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. *Journal of the American College of Cardiology*, *58*, 2241–2247. https://doi.org/10.1016/j.jacc.2011.08.025

Wilson, R. L., Yuan, V., Courtney, J. A., Tipler, A., Cnota, J. F., & Jones, H. N. (2022). Analysis of commonly expressed genes between first trimester fetal heart and placenta cell types in the context of congenital heart disease. *Scientific Reports*, *12*, 10756. https://doi.org/10.1038/s41598-022-14955-8

Yu, J. S., & Cui, W. (2016). Proliferation, survival and metabolism: The role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. *Development*, *143*, 3050–3060.

Zmijanac Partl, J., Karin, V., Skrtic, A., Nikuseva-Martic, T., Serman, A., Mlinarec, J., Curkovic-Perica, M., Vranic, S., & Serman, L. (2018). Negative regulators of Wnt signaling pathway SFRP1 and SFRP3 expression in preterm and term pathologic placentas. *The Journal of Maternal-Fetal & Neonatal Medicine*, *31*, 2971–2979.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Fresch, R., Courtney, J., Brockway, H., Wilson, R. L., & Jones, H. (2023). HAND1 knockdown disrupts trophoblast global gene expression. *Physiological Reports*, *11*, e15553. https://doi.org/10.14814/phy2.15553